SCHEMBL19852623

SCHEMBL19852623

CCCC(C)c1[nH]nc2ccccc12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.42
CYP2C19 P33261 1/20 0.42
NOS1 P29475 1/20 0.42
DRD2 P14416 1/20 0.40
SLC6A4 P31645 1/20 0.40
KDM4E B2RXH2 1/20 0.36
ALDH1A1 P00352 1/20 0.36
GAA P10253 1/20 0.36
HPGD P15428 1/20 0.36
FFAR1 O14842 1/20 0.35
GPR84 Q9NQS5 1/20 0.35
ELANE P08246 3/20 0.33
PIK3CA P42336 2/20 0.33
MTOR P42345 2/20 0.33
PDK1 Q15118 2/20 0.33
MPO P05164 1/20 0.33
PIK3CD O00329 1/20 0.33
PIK3CG P48736 1/20 0.33
ADORA3 P0DMS8 1/20 0.33
CACNA2D1 P54289 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20214878 0.90 CYP1A2 (0.40) CYP1A2CYP2C19NOS1DRD2SLC6A4
SCHEMBL18559460 0.86 CYP1A2 (0.44) CYP1A2CYP2C19NOS1DRD2SLC6A4
SCHEMBL18556889 0.80 KDM4C (0.38) KDM4E
SCHEMBL6842156 0.78 CYP1A2 (0.50) CYP1A2CYP2C19NOS1DRD2SLC6A4
SCHEMBL20676148 0.77 NOS1 (0.50) CYP1A2CYP2C19NOS1DRD2SLC6A4
SCHEMBL27580013 0.74 CYP1A2 (0.37) CYP1A2CYP2C19NOS1DRD2SLC6A4
SCHEMBL19308820 0.70 KDM4E (0.43) CYP1A2CYP2C19KDM4EALDH1A1GAA
SCHEMBL29303865 0.68 FFAR1 (0.33) FFAR1GPR84ELANEMPO
SCHEMBL19853487 0.67 CYP1A2 (0.50) CYP1A2CYP2C19NOS1DRD2SLC6A4
SCHEMBL21362866 0.67 SMN1; SMN2 (0.43) CYP1A2CYP2C19ALDH1A1GAAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11352343-B2 Urea derivatives and uses thereof KALA PHARMACEUTICALS, INC. (US) 2022-06-07 US disclosed
US-20200299272-A1 Urea Derivatives and Uses Thereof KALA BIO, Inc. 2020-09-24 US disclosed
US-20180037573-A1 UREA DERIVATIVES AND USES THEREOF KALA BIO, Inc. 2018-02-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11352343-B2 Urea derivatives and uses thereof UACA, RB1, FLT1 CYP1A2 3517/4885CYP2C19 1538/4885NOS1 43/4885
US-20180037573-A1 UREA DERIVATIVES AND USES THEREOF UACA, RB1, FLT1 CYP1A2 3517/4885CYP2C19 1538/4885NOS1 43/4885
US-20200299272-A1 Urea Derivatives and Uses Thereof UACA, RB1, FLT1 CYP1A2 3517/4885CYP2C19 1538/4885NOS1 43/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.